Homburger advised Santhera in connection with its licensing of a product candidate for the treatment of cystic fibrosis from Polyphor
On February 15, 2018, Santhera Pharmaceuticals Holding AG (SIX: SANN) announced that it had obtained a world-wide exclusive license from Swiss pharmaceutical company Polyphor AG to develop and commercialize a clinical stage product candidate for the treatment of cystic fibrosis and other pulmonary diseases. Santhera paid the upfront payment of CHF 6.5 m in newly-issued shares representing 3.8% of Santhera’s share capital. The license also provides for cash milestone payments of up to CHF 121 m and other royalty and milestone payments.
Homburger advised Santhera on the Swiss corporate and securities law aspects of the transaction. The Homburger team was led by partner Dieter Gericke and comprised Daniel Häusermann (both Corporate / M&A).